Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) is a provider of injectable solutions and services that support the containment and delivery of medicines for pharmaceutical, biotechnology and generic drug companies. News related to WST often centers on its role in injectable drug administration, its proprietary product platforms and its contract manufacturing activities.
Company announcements frequently include quarterly and annual financial results, updates to revenue and earnings guidance, and details on performance in its Proprietary Products and Contract-Manufactured Products segments. Releases have highlighted trends in High-Value Product Components and High-Value Product Delivery Devices, as well as demand for self-injection devices for therapeutic areas such as obesity and diabetes.
West’s news flow also covers product and technology developments. Recent examples include the launch of the West Synchrony™ Prefillable Syringe System, described as a system-level solution for biologics and vaccines, and updates on the SmartDose® on-body delivery platform. The company has announced a definitive agreement to sell manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie, along with related information on continued supply and ongoing project commitments.
Investors following WST news will also see disclosures about capital allocation, such as dividends and share repurchases, as well as governance and leadership changes reported via press releases and Form 8-K filings. Conference participation and investor presentations are regularly announced, providing additional context on the company’s strategy and financial outlook. This news page aggregates such updates so readers can review West’s latest reported developments, financial communications and product-related announcements in one place.
West Pharmaceutical Services (NYSE: WST) will present at two investor conferences in May and June 2026. The company will speak at the Bank of America Global Healthcare Conference on May 12, 2026 and the William Blair Annual Growth Stock Conference on June 2, 2026.
Live webcasts will be available in the Investors section of the company website, with replays accessible for approximately 90 days after each event.
West Pharmaceutical Services (NYSE: WST) reported Q1 2026 net sales $844.9M (+21.0%) and diluted EPS $1.92 (+56.1%). Adjusted-diluted EPS was $2.13 (+46.9%). Operating cash flow was $89.9M and free cash flow $47.2M. The company repurchased 1.2M shares for $297.6M.
West raised full-year 2026 guidance: net sales to $3.295B–$3.350B and adjusted-diluted EPS to $8.40–$8.75. Q2 sales guidance: $830M–$850M.
West Pharmaceutical Services (NYSE: WST) will release first-quarter 2026 financial results before the market opens on Thursday, April 23, 2026 and will host a conference call at 8:00 a.m. Eastern Time to discuss results and business expectations.
A live webcast, registration details for telephone Q&A with a unique PIN, a slide presentation on the investor website, and an approximately 90-day replay will be available.
West (NYSE: WST) opened a new 165,000 square foot building at its Damastown, Dublin site on March 31, 2026 to expand contract services for high-volume injectable therapies.
The expansion adds advanced automation and commercial-scale drug-handling to existing molding, device assembly and packaging capabilities and is part of the West Vantage integrated contract services offering.
West Pharmaceutical Services (NYSE: WST) announced that Eric M. Green plans to retire as President, CEO and Chair once a successor is hired, with the Board expecting the transition in the second half of 2026. The Board has engaged a leading executive recruiting firm and the company reaffirmed guidance from February 12, 2026. Green served 11 years as CEO, during which the company more than doubled sales and delivered approximately 350% total shareholder return. The company emphasized its position as a leading provider of injectable solutions and plans a structured leadership handover to preserve momentum.
West Pharmaceutical Services (NYSE: WST) will present at two investor conferences in March 2026: a Barclays Global Healthcare fireside chat at 9:00 AM EDT on March 10, 2026 and a KBCM Healthcare Forum fireside chat at 1:30 PM EDT on March 18, 2026.
Live webcasts will be available in the Investors section of the company website, with replays accessible for approximately 90 days after each event.
West (NYSE: WST) declared a $0.22 per share regular quarterly dividend payable May 6, 2026, to shareholders of record on April 29, 2026. The board also authorized a new $1.0 billion share repurchase program on February 17, 2026, with no expiration date.
Repurchases may occur on the open market, via pre-set trading plans, in negotiated transactions, or other lawful methods; the program is discretionary and may be suspended or terminated. The prior program was fully utilized before its December 31, 2025 expiration.
West Pharmaceutical Services (NYSE: WST) reported strong fourth-quarter and full-year 2025 results with net sales of $805.0M in 4Q (+7.5%) and full-year net sales of $3.074B (+6.3%). Adjusted-diluted EPS was $2.04 in 4Q (+12.1%) and $7.29 for FY2025 (+8.0%).
Operating cash flow rose 15.5% to $754.8M and free cash flow increased 69.6% to $468.9M. The company repurchased $134.0M of shares in 2025. Fiscal 2026 guidance: net sales $3.215B–$3.275B and adjusted-diluted EPS $7.85–$8.20.
West (NYSE: WST) will release fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 12, 2026, followed by a conference call at 8:00 a.m. Eastern Time. A live webcast, slide presentation and 90-day replay will be available on the company's investor website.
West Pharmaceutical Services (NYSE: WST) announced the global commercial availability of the West Synchrony™ S1 prefillable syringe (PFS) system at Pharmapack 2026 in Paris on January 20, 2026. The system offers 1 ml long and 2.25 ml staked needle options for biologics, plus 1 ml standard staked needle and Luer lock options for vaccines, with rigid or soft needle shields and integrated tip caps. The platform includes West NovaPure® and FluroTec™ barrier film plungers. West will present learning labs and a product gallery at Pharmapack on January 21–22, 2026 to highlight integrated solutions and combination-product support.